Marc Wilson - Jun 20, 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
CFO
Signature
/s/ Marc Wilson
Stock symbol
CRNX
Transactions as of
Jun 20, 2023
Transactions value $
-$431,803
Form type
4
Date filed
6/21/2023, 05:32 PM
Previous filing
Mar 17, 2023
Next filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$218K -10.9K -10.3% $19.96 95.2K Jun 20, 2023 Direct F1
transaction CRNX Common Stock Options Exercise $186K +20K +21.02% $9.28 115K Jun 20, 2023 Direct
transaction CRNX Common Stock Sale -$399K -20K -17.37% $19.97 95.2K Jun 20, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -20K -21.93% $0.00 71.2K Jun 20, 2023 Common Stock 20K $9.28 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.96 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $19.97 per share. The range of sales prices on the transaction date was $19.86 to $20.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F3 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.